mVASC® is a processed human microvascular tissue allograft containing structural tissue fragments, associated nonviable cells, and inherent biological factors that enhance healing potential by increasing blood supply and providing the foundation for tissue repair.
• Can be used wherever microvascular deficiencies exist. For example, mVASC® can be added to a nonhealing wound to restore blood flow and heal the wound.
• Increased complete wound closure at 12 weeks
• Increased percent wound area reduction from weeks 4 through 12
• Decreased time to healing
• Improved local neuropathy
• Increased perfusion and improved regional neuropathy
mVASC® is restricted to homologous use for the repair, reconstruction, replacement, or supplementation of microvascular tissues.
The mVASC® manufacturing process involves exposure to Gentamycin, and Clindamycin. The safety of product use for patients with hypersensitivities to these antibiotics is unknown. The mVASC® manufacturing process involves exposure to collagenase and neutral proteases. The safety of product use for patients with hypersensitivities to these compounds is unknown. The mVASC® microvascular tissue treatment is not suitable for intravenous injection.
Processing of the human tissue, laboratory testing and careful donor screening reduces the risks of donor tissue transmitting disease to the recipient patient. As with any processed donor tissue, there is still a potential for the transmission of infectious diseases.
No long-term studies have been conducted to evaluate the carcinogenic or mutagenic potential or reproductive impact of the clinical application of mVASC® microvascular tissue treatment.
Do not resterilize.
Do not use if expiration date has been exceeded or if there is evidence of defects in the package or label integrity.
Restricted to use by a licensed clinician.
The physician is responsible for determining the appropriate amount and use of mVASC® microvascular tissue for each application.
Health care practitioners are responsible for maintaining recipient records for the purpose of tracing tissue post-implantation. Patient tracking labels are provided for this purpose.
Normal rehydration of mVASC® microvascular tissue is usually accomplished in two minutes.
Do not centrifuge.
Do not use if the package seal is broken.
Unused or expired product should be discarded in accordance with local, state and institutional human issue disposal requirements.
Donor screening methods are limited, therefore certain diseases may not be detected. The following complications of tissue transplantation may occur:
- Transmission of known infectious agents including but not limited to viruses and fungi.
- Transmission or causation of diseases of unknown etiology and characteristics.
Adverse reactions associated with mVASC® microvascular tissue or the implant procedure include:
- Wound dehiscence
- Disease transmission
- Hypersensitive, allergic or other immune response
mVASC® is stable for five years when stored at room temperature. Store in a cool, dry place and in a manner that protects the integrity of the package and sterile barrier
|Assigned HCPCS code|
|Shelf life greater than 2 years||●|
|Shelf life limited|
|Indicated for acute wounds||●|
|Indicated for chronic wounds||●|
|Indicated for diabetic ulcers||●|
|Indicated for pressure ulcers||●|
|Indicated for surgical wounds||●|
|Indicated for third-degree burns|
|Indicated for venous ulcers||●|
|Contact manufacturer for usage guidelines||●|
|Educational Material Available||●|
|Free Samples/Trials Available||●|
|Published Clinical Article Available||●|
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
mVASC® can be applied topically, or rehydrated with sterile water and implanted.
mVASC® should be applied weekly, and remain undisturbed between applications.
Microvascular Tissues, Inc. (MVT) is an evidence-based regenerative medicine company developing and commercializing products that address vascular deficiencies using vascular solutions, including mVASC®, an allogeneic structural microvascular tissue graft.